

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 13F

OMB APPROVAL

OMB Number: 3235-0006

Estimated average burden

hours per response: 23.8

FORM 13F COVER PAGE

Report for the Calendar Year or Quarter Ended: 06-30-2026

Check here if Amendment: ☐ Amendment Number: _____

This Amendment (Check only one.): ☐ is a restatement.

☐ adds new holdings entries.

Institutional Investment Manager Filing this Report:

Name: Merck & Co., Inc.

Address: 126 EAST LINCOLN AVENUE

P.O. BOX 2000

RAHWAY NJ 07065

Form 13F File Number: 028-25193

CRD Number (if applicable): _____

SEC File Number (if applicable): _____

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:

Name: Kelly Grez

Title: Corporate Secretary

Phone: 9087404000

Signature, Place, and Date of Signing:

/s/ Kelly Grez Rahway, NEW JERSEY 08-07-2026
[Signature] [City, State] [Date]

Do you wish to provide information pursuant to Special Instruction 5?

☐ Yes ☒ No

Report Type (Check only one.):

☒ 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)

☐ 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)

☐ 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

Form 13F Summary Page

Report Summary:

Number of Other Included Managers:	<u>1</u>
Form 13F Information table Entry Total:	<u>13</u>
Form 13F Information table Value Total:	<u>526,407,169</u> (round to nearest dollar)

List of Other Included Managers:

Provide a numbered list of the name(s) and Form 13F number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.

No.	Name	Form 13F File Number	CRD No. (if applicable)	SEC File No. (if applicable)	CIK
<u>1</u>	<u>MERCK SHARP & DOHME LLC</u>	<u></u>	<u></u>	<u></u>	<u>0000064978</u>

FORM 13F INFORMATION TABLE

COLUMN 1	COLUMN 2	COLUMN 3		COLUMN 4		COLUMN 5		COLUMN 6	COLUMN 7	COLUMN 8		
NAME OF ISSUER	TITLE OF CLASS	CUSIP	FIGI	VALUE (round to nearest dollar)	SHRS OR PRN AMT	SH / PRN	PUT / CALL	INVESTMENT DISCRETION	OTHER MANAGER	VOTING AUTHORITY		
										SOLE	SHARED	NONE
AKTIS ONCOLOGY INC	COM	01021M104	-	30,710,162	952,844	SH	-	DFND	-	0	952,844	0
ALECTOR INC	COM	014442107	-	7,126,896	3,545,719	SH	-	DFND	-	0	3,545,719	0
EIKON THERAPEUTICS INC	COM	282564103	-	21,749,991	1,666,666	SH	-	DFND	-	0	1,666,666	0
ENTRADA THERAPEUTICS INC	COM	29384C108	-	12,804,692	1,739,768	SH	-	DFND	-	0	1,739,768	0
EVAXION BIOTECH A/S	SPONSORED ADS	29970R303	-	3,763,791	1,214,126	SH	-	DFND	-	0	1,214,126	0
KYMERA THERAPEUTICS INC	COM	501575104	-	88,544,161	772,165	SH	-	DFND	-	0	772,165	0
MODERNA INC	COM	60770K107	-	161,642,545	2,308,190	SH	-	DFND	1	0	2,308,190	0
NEUPHORIA THERAPEUTICS INC	COM	64136E102	-	43,818	10,027	SH	-	DFND	1	0	10,027	0
PERSONALIS INC	COM	71535D106	-	188,202,236	14,044,943	SH	-	DFND	1	0	14,044,943	0
SUTRO BIOPHARMA INC	COM	869367201	-	9,042,053	272,351	SH	-	DFND	1	0	272,351	0
TUHURA BIOSCIENCES INC	COM	898920103	-	45,501	19,445	SH	-	DFND	1	0	19,445	0
VIRIDIAN THERAPEUTICS INC	COM	92790C104	-	1,716,015	93,414	SH	-	DFND	-	0	93,414	0
XILIO THERAPEUTICS INC	COM	98422T209	-	1,015,308	105,982	SH	-	DFND	-	0	105,982	0